Keros Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>Keros Therapeutics will host its 2024 Annual Meeting of Stockholders virtually on May 30, 2024, providing access to proxy materials online.</b>

AI Summary

Keros Therapeutics, Inc. (KROS) filed a Proxy Statement (DEF 14A) with the SEC on April 17, 2024. Keros Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders via live audio webcast on May 30, 2024, at 9:00 a.m. Eastern time. The meeting will be conducted in a virtual format, with no physical in-person meeting. Stockholders will have the same rights and opportunities to participate as they would at an in-person meeting. Proxy materials are being provided over the internet under SEC's 'notice and access' rules, with a notice mailed instead of paper copies. The notice includes instructions on accessing documents online and requesting paper copies.

Why It Matters

For investors and stakeholders tracking Keros Therapeutics, Inc., this filing contains several important signals. The virtual format aims to increase stockholder access to information while reducing environmental impact and costs associated with physical meetings. Providing materials online and via notice allows for efficient distribution and encourages stockholder participation in corporate governance.

Risk Assessment

Risk Level: — Keros Therapeutics, Inc. shows moderate risk based on this filing. The filing is a routine proxy statement for an annual meeting, containing no new material financial or operational information that would indicate significant risk.

Analyst Insight

Stockholders should review the proxy materials to understand the agenda for the annual meeting and exercise their voting rights.

Key Numbers

• 2024 — Annual Meeting Year (Year of the Annual Meeting of Stockholders.)
• May 30 — Meeting Date (Date of the 2024 Annual Meeting.)
• 9:00 a.m. Eastern time — Meeting Time (Time of the 2024 Annual Meeting.)

Key Players & Entities

• Keros Therapeutics, Inc. (company) — Registrant and filer of the proxy statement.
• 2024 Annual Meeting of Stockholders (event) — The subject of the proxy statement.
• May 30, 2024 (date) — Date of the Annual Meeting.
• 9:00 a.m. Eastern time (time) — Time of the Annual Meeting.
• U.S. Securities and Exchange Commission (regulator) — Regulator whose rules are being followed for proxy material distribution.

FAQ

Industry Context

Keros Therapeutics operates in the pharmaceutical preparations industry, focusing on developing novel treatments.

Regulatory Implications

The filing adheres to regulations set by the U.S. Securities and Exchange Commission (SEC) regarding proxy solicitations and annual meetings.

What Investors Should Do

1. Review the proxy statement for details on meeting agenda items and voting procedures.
2. Log in to the virtual meeting platform before the start time on May 30, 2024.
3. Consider requesting paper copies of proxy materials if preferred over online access.

Key Dates

• 2024-05-30: 2024 Annual Meeting of Stockholders — Key date for stockholder participation and voting.
• 2024-04-17: Filing Date of Proxy Statement — Indicates when the company made the proxy materials public.

Year-Over-Year Comparison

This is a DEF 14A filing for the 2024 Annual Meeting, following the typical format for such disclosures.

Filing Documents

• tm242787d6_def14a.htm (DEF 14A) — 1070KB
• lg_kerostherapeutics-4clr.jpg (GRAPHIC) — 11KB
• sg_jasbirseehra-4c.jpg (GRAPHIC) — 8KB
• sg_esthercho-bw.jpg (GRAPHIC) — 5KB
• bc_capvsnetloss-4c.jpg (GRAPHIC) — 46KB
• bc_capvstsr-4c.jpg (GRAPHIC) — 59KB
• px_24kerosproxy01pg01-4c.jpg (GRAPHIC) — 300KB
• px_24kerosproxy01pg02-4c.jpg (GRAPHIC) — 396KB
• 0001104659-24-048301.txt (&nbsp;) — 4013KB
• kros-20231231.xsd (EX-101.SCH) — 9KB
• kros-20231231_def.xml (EX-101.DEF) — 5KB
• kros-20231231_lab.xml (EX-101.LAB) — 35KB
• kros-20231231_pre.xml (EX-101.PRE) — 10KB
• tm242787d6_def14a_htm.xml (XML) — 191KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 26 EXECUTIVE OFFICERS 29 COMPENSATION DISCUSSION AND ANALYSIS 30

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 44

(V) PAY VERSUS PERFORMANCE

ITEM 402(V) PAY VERSUS PERFORMANCE 52 NON-EMPLOYEE DIRECTOR COMPENSATION 56 EQUITY COMPENSATION PLAN INFORMATION 59 TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION 60 HOUSEHOLDING OF PROXY MATERIALS 62 OTHER MATTERS 63 i TABLE OF CONTENTS KEROS THERAPEUTICS, INC. 1050 Waltham Street, Suite 302 Lexington, Massachusetts 02421 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held On May 30, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Who is soliciting my vote? We are providing you with these proxy materials because the Board of Directors (the " Board ") of Keros Therapeutics, Inc. (the " Company ") is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders (the " Annual Meeting ") of the Company, including at any adjournments or postponements thereof, to be held on Thursday, May 30, 2024 at 9:00 a.m. Eastern time in a virtual meeting format only, live via audio webcast. Do I need to attend the Annual Meeting to vote? You are invited to attend the Annual Meeting to vote on the proposals described in this proxy statement (the " Proxy Statement "). However, you do not need to attend the Annual Meeting to vote your shares. Instead, you may simply follow the instructions below to submit your proxy over the telephone, through internet or by mail, and your votes will be cast for you at the Annual Meeting. The proxy materials, including this Proxy Statement and our Annual Report on Form 10-K for the year ended December 31, 2023, are being distributed and made available on or about April 17, 2024. As used in this Proxy Statement, references to "we," "us," "our," "Keros" and the "Company" refer to Keros Therapeutics, Inc. and our consolidated subsidiaries. Why did I receive a notice regarding the availability of proxy materials on the internet instead of a full set of proxy materials? Pursuant to rules adopted by the Securities and Exchange Commission (the " SEC "), we h

View Full Filing

View this DEF 14A filing on SEC EDGAR